S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns

Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis

$23.07
+1.63 (+7.60%)
(As of 03/27/2024 ET)
Today's Range
$21.69
$23.26
50-Day Range
$19.71
$24.57
52-Week Range
$11.22
$25.34
Volume
1.19 million shs
Average Volume
1.31 million shs
Market Capitalization
$1.96 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.42

Syndax Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
49.2% Upside
$34.42 Price Target
Short Interest
Healthy
9.80% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.54mentions of Syndax Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.70) to ($2.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.93 out of 5 stars

Medical Sector

227th out of 939 stocks

Pharmaceutical Preparations Industry

100th out of 422 stocks

SNDX stock logo

About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

SNDX Stock Price History

SNDX Stock News Headlines

Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
SNDX Apr 2024 17.500 put
Scotiabank Keeps Their Hold Rating on Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals: Q4 Earnings Insights
Earnings Preview: Syndax Pharmaceuticals
See More Headlines
Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/27/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SNDX
Employees
184
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.42
High Stock Price Target
$45.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+49.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-209,360,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$139.71 million
Book Value
$6.53 per share

Miscellaneous

Free Float
80,972,000
Market Cap
$1.96 billion
Optionable
Optionable
Beta
1.03
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Michael A. Metzger M.B.A.Mr. Michael A. Metzger M.B.A. (Age 53)
    CEO & Director
    Comp: $1.05M
  • Mr. Keith Alan Goldan CPA (Age 53)
    CFO, Treasurer & Chief Accounting Officer
    Comp: $649.07k
  • Mr. Luke J. Albrecht (Age 44)
    Senior VP, General Counsel & Secretary
    Comp: $605.82k
  • Dr. Catherine Madigan M.D. (Age 51)
    Chief Medical Officer
    Comp: $764.41k
  • Mr. Steve M. Sabus (Age 57)
    Chief Commercial Officer
    Comp: $523.44k
  • Dr. Neil Gallagher M.D.
    Ph.D., President, Head of Research & Development
  • Dr. Peter Ordentlich B.Sc. (Age 55)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Dr. Richard A. Heyman Ph.D. (Age 67)
    Co-Founder
  • Dr. Ronald M. Evans Ph.D. (Age 75)
    Co-Founder, Advisor and Chair of Scientific Advisory Board
  • Dr. Michael Downes Ph.D.
    Co-Founder

SNDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Syndax Pharmaceuticals stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SNDX shares.
View SNDX analyst ratings
or view top-rated stocks.

What is Syndax Pharmaceuticals' stock price target for 2024?

10 Wall Street analysts have issued 12 month target prices for Syndax Pharmaceuticals' shares. Their SNDX share price targets range from $23.00 to $45.00. On average, they anticipate the company's share price to reach $34.42 in the next year. This suggests a possible upside of 49.2% from the stock's current price.
View analysts price targets for SNDX
or view top-rated stocks among Wall Street analysts.

How have SNDX shares performed in 2024?

Syndax Pharmaceuticals' stock was trading at $21.61 on January 1st, 2024. Since then, SNDX stock has increased by 6.8% and is now trading at $23.07.
View the best growth stocks for 2024 here
.

When is Syndax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our SNDX earnings forecast
.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced its quarterly earnings results on Tuesday, February, 27th. The company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by $0.01. During the same period in the previous year, the business posted ($0.62) earnings per share.

What ETFs hold Syndax Pharmaceuticals' stock?

ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Simplify Health Care ETF (PINK).

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

When did Syndax Pharmaceuticals IPO?

Syndax Pharmaceuticals (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Who are Syndax Pharmaceuticals' major shareholders?

Syndax Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (8.93%), Kynam Capital Management LP (6.67%), Vanguard Group Inc. (5.11%), Vanguard Group Inc. (5.10%), Avoro Capital Advisors LLC (4.98%) and Avidity Partners Management LP (4.66%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Keith A Goldan, Keith Katkin, Michael A Metzger, Michael L Meyers, Peter Ordentlich, Pierre Legault and William Meury.
View institutional ownership trends
.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNDX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners